- Trials with a EudraCT protocol (3,374)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (81)
3,374 result(s) found for: Lesions.
Displaying page 1 of 169.
| EudraCT Number: 2012-002335-28 | Sponsor Protocol Number: UMCGABR40641 | Start Date*: 2013-01-07 |
| Sponsor Name:University medical centre groningen | ||
| Full Title: Evaluation of VEGF expression with 89Zr-bevacizumab PET scan in patients with relapsing multiple myeloma; a feasibility study | ||
| Medical condition: patients with relapsing multiple myeloma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-004170-25 | Sponsor Protocol Number: MH-110 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Bracco Imaging S.p.A. | ||
| Full Title: A PHASE III, MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE SAFETY AND EFFICACY OF MULTIHANCE® AT THE DOSE OF 0.10 mmol/kg IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC PA... | ||
| Medical condition: imaging diagnosis of highly suspected or known brain and/or spine disease, which are known to impair the Blood Brain Barrier Function | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) BE (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-000875-20 | Sponsor Protocol Number: C3291028 | Start Date*: 2020-05-14 |
| Sponsor Name:Pfizer Inc. | ||
| Full Title: A Phase 2b, Multi Center, Randomized, Double-Blind, Vehicle-Controlled, Intra-Participant Study, to Evaluate Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Pediatric and... | ||
| Medical condition: Atopic Dermatitis | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2011-002692-42 | Sponsor Protocol Number: 1.1_2011 | Start Date*: 2012-06-20 |
| Sponsor Name:MUW-Medical University of Vienna,Medizinische Universität Wien | ||
| Full Title: Characterization of myeloma bone lesions - before and during anti-cancer therapy - using 18F-FDG-, 18F-fluoride PET/CT and MRI- a pilot study | ||
| Medical condition: The primary aim of this study is the characterization of WB MRI detected untreated MM bone lesions in consideration of the mineralization status and tumor activity using 18F-fluorid-PET/CT and 18F ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-002871-18 | Sponsor Protocol Number: A-92-52030-166 | Start Date*: 2006-02-09 |
| Sponsor Name:IPSEN PHARMA, S.A. | ||
| Full Title: Phase II, open, single group,multicentre study to evaluate the efficacy and safety of Somatuline Autogel® (120 mg) administered every 4 weeks by deep subcutaneous injection in the tumour´s growth s... | ||
| Medical condition: Patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-005788-24 | Sponsor Protocol Number: BA2005/21/02 | Start Date*: 2007-02-15 |
| Sponsor Name:Bioalliance Pharma | ||
| Full Title: A Randomised, Double-Blind, Single dose, One-Day Early Administration, Multicentre Study comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg muco-adhesive buccal tablet to matching Placebo... | ||
| Medical condition: Herpes labialis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Completed) DE (Completed) FR (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-014724-32 | Sponsor Protocol Number: SABA | Start Date*: Information not available in EudraCT |
| Sponsor Name:University Medical Center Eppendorf | ||
| Full Title: SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS): A MRI-CONTROLLED, MULTICENTER, BASELINE-TO-TREATMENT, 32-WEEK... | ||
| Medical condition: Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-002483-31 | Sponsor Protocol Number: UZBRU_VHH2_2 | Start Date*: 2020-11-30 |
| Sponsor Name:UZ Brussel | ||
| Full Title: Phase II study to evaluate the clinical potential of 68GaNOTA-Anti-MMR-VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in oncological lesions, ... | ||
| Medical condition: C1: malignancies of the head and neck. C2: malignancy with a solid component C3: carotid plaque, planned for (SOC) carotid endarterectomy. C4: biopsy-proven Hodgkin or non-Hodgkin lymphoma. C5: su... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-011479-62 | Sponsor Protocol Number: 20090313 | Start Date*: 2009-07-24 |
| Sponsor Name:University Medical Center Groningen | ||
| Full Title: Visualizing VEGF producing lesions in Von Hippel-Lindau disease | ||
| Medical condition: To determine if disease associated lesions in patients with VHLD can be visualized with 89Zr-bevacizumab PET scans. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-003086-40 | Sponsor Protocol Number: PIX001 | Start Date*: 2008-04-08 |
| Sponsor Name:Fondation Charcot Stichting | ||
| Full Title: A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS) | ||
| Medical condition: aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-002285-12 | Sponsor Protocol Number: OJ-KDC01 | Start Date*: 2019-12-02 |
| Sponsor Name:LABORATORIO OJER PHARMA, S.L. | ||
| Full Title: An exploratory, multicenter, randomized, open-label with blind evaluation, active-controlled study to evaluate the safety and efficacy of Keramod (imiquimod 50 mg/g, Gel) compared with Aldara (imi... | ||
| Medical condition: ACTINIC QUERATOSIS, also known as solar keratosis, is a skin disease caused by chronic exposure to sunlight. It appears as scaly lesions on the skin as a result of an abnormal growth of the cells i... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-004736-79 | Sponsor Protocol Number: 1102-CT02 | Start Date*: 2007-03-06 |
| Sponsor Name:Antisense Therapeutics Ltd. | ||
| Full Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous inje... | ||
| Medical condition: To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: CZ (Completed) SK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-005184-29 | Sponsor Protocol Number: P305-R-EG04 | Start Date*: 2006-02-21 |
| Sponsor Name:GABA GmbH | ||
| Full Title: Prevention of incipient carious lesions (white spot lesions) in patients with fixed orthodontic appliances following the application of elmex® gelée | ||
| Medical condition: incipient carious lesions (white spot lesions) | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-001260-34 | Sponsor Protocol Number: 414520 | Start Date*: 2014-09-09 |
| Sponsor Name:Maastricht University Medical Center | ||
| Full Title: TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): a randomized controlled trial | ||
| Medical condition: High grade cervical intraepithelial neoplasia. | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-003326-44 | Sponsor Protocol Number: TIRBA-2022-02 | Start Date*: 2023-04-11 |
| Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Dermatologie und Venerologie | ||
| Full Title: SunDamage: Tirbanibulin 1% Ointment for the treatment of chronically sun-damaged skin on the face | ||
| Medical condition: Subclinical lesions in UV-exposed areas of chronically UV-damaged skin in the face adjacent to lesions caused by actinic keratosis but not obviously affected themselves. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-005035-33 | Sponsor Protocol Number: R2477-FOP-1623 | Start Date*: 2017-08-15 | |||||||||||
| Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progres... | |||||||||||||
| Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000456-19 | Sponsor Protocol Number: BC-09501 | Start Date*: 2021-11-17 |
| Sponsor Name:University Hospital Ghent | ||
| Full Title: Use of 18F-PSMA-11 PET for detection of lesions in iodine refractory thyroid cancers | ||
| Medical condition: Patients with a iodine refractory thyroid carcinoma, who received an 18F -FDG PET/CT scan in routine clinical practice. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-004538-32 | Sponsor Protocol Number: LIMTOP-I | Start Date*: 2012-04-04 | |||||||||||
| Sponsor Name:Moberg Derma | |||||||||||||
| Full Title: A double-blind, randomized, multi-centre, vehicle-controlled study of efficacy and safety of a new topical formulation with imiquimod (Limtop) applied 1,3 or 7 times weekly during 2 x 2 weeks treat... | |||||||||||||
| Medical condition: 5-20 clinically confirmed, palpable or visible (grade I or II according to modified Olsen score), nonhyperkeratotic, nonhypertrophic, AK lesions located within a contiguous (25 - 100 cm²) area on t... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001750-29 | Sponsor Protocol Number: ZORRO | Start Date*: 2022-07-30 |
| Sponsor Name:AUVA Trauma Center Vienna | ||
| Full Title: Influence of zoledronic acid on healing after arthroscopic repair of chronic rotator cuff lesions - A prospective, randomized, placebo-controlled phase II trial | ||
| Medical condition: INFLUENCE OF ZOLEDRONIC ACID ON HEALING AFTER ARTHROSCOPIC REPAIR OF CHRONIC ROTATOR CUFF LESIONS | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004853-26 | Sponsor Protocol Number: T315/2018 | Start Date*: 2019-03-25 | ||||||||||||||||
| Sponsor Name:Turku University Hospital | ||||||||||||||||||
| Full Title: The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic prostate cancer | ||||||||||||||||||
| Medical condition: Metastatic prostate cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
| Trial protocol: FI (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
